Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Debt (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Total Debt for 15 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 65.69% to $5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, down 65.69% year-over-year, with the annual reading at $5.2 million for FY2025, 65.69% down from the prior year.
  • Total Debt hit $5.2 million in Q4 2025 for Cumberland Pharmaceuticals, roughly flat from $5.2 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $20.0 million in Q1 2022 to a low of $5.2 million in Q1 2025.
  • Historically, Total Debt has averaged $13.6 million across 5 years, with a median of $15.0 million in 2021.
  • Biggest five-year swings in Total Debt: skyrocketed 35.71% in 2022 and later plummeted 67.43% in 2025.
  • Year by year, Total Debt stood at $15.0 million in 2021, then increased by 8.0% to $16.2 million in 2022, then fell by 21.09% to $12.8 million in 2023, then grew by 19.49% to $15.3 million in 2024, then plummeted by 65.69% to $5.2 million in 2025.
  • Business Quant data shows Total Debt for CPIX at $5.2 million in Q4 2025, $5.2 million in Q3 2025, and $5.2 million in Q2 2025.